Skip to main content

Advertisement

SpringerLink
Log in

New understanding and treatments for osteoporosis

  • New Horizons in
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

To summarize promising areas of investigation in osteoporosis and to stimulate further research in this area, as discussed in a recent international conference. Over the recent years, there has been an improvement in the knowledge of molecular pathways involved in bone formation and resorption with the development of new drugs to treat osteoporosis. Intact parathyroid hormone, teriparatide, and anti-sclerostin monoclonal antibody are anabolic drugs, whereas denosumab and odanacatib are anti-resorptive drugs with more reversible effects as compared to bisphosphonates. Anabolic and anti-resorptive agents have different effects on bone, and research in this area includes the efficacy of combination and sequential therapies with them. New insights in the molecular pathways of bone remodeling have clarified the mechanisms responsible for skeletal fragility in several forms of secondary osteoporosis, such as that occurring in type 2 diabetes, following drug exposure and systemic inflammatory diseases. Future research is needed to address the efficacy of anti-osteoporotic drugs in these more recently recognized conditions of skeletal fragility. Osteoporosis continues to be an important field of biomedical research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. E.A. Chrischilles, C.D. Butler, C.S. Davis, R.B. Wallace, A model of lifetime osteoporosis impact. Arch. Intern. Med. 51, 2026–2032 (1991)

    Article  Google Scholar 

  2. S. Khosla, S. Amin, E. Orwoll, Osteoporosis in men. Endocr. Rev. 29, 441–464 (2008)

    Article  PubMed  CAS  Google Scholar 

  3. M. Almeida, L. Han, E. Ambrogini, S.M. Bartell, S.C. Manolagas, Oxidative stress stimulates apoptosis and activates NF-kappaB in osteoblastic cells via a PKCbeta/p66shc signaling cascade: counter regulation by estrogens or androgens. Mol. Endocrinol. 24, 2030–2037 (2010)

    Article  PubMed  CAS  Google Scholar 

  4. E. Ambrogini, M. Almeida, M. Martin-Millan, J.H. Paik, R.A. Depinho, L. Han, J. Goellner, R.S. Weinstein, R.L. Jilka, C.A. O’Brien, S.C. Manolagas, FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab. 11, 136–146 (2010)

    Article  PubMed  CAS  Google Scholar 

  5. S.C. Manolagas, De-fense! De-fense! De-fense: scavenging H2O2 while making cholesterol. Endocrinology 149, 3264–3266 (2008)

    Article  PubMed  CAS  Google Scholar 

  6. M. Almeida, M. Martin-Millan, E. Ambrogini III, R. Bradsher, L. Han, X.D. Chen, P.K. Roberson, R.S. Weinstein, C.A. O’Brien, R.L. Jilka, S.C. Manolagas, Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERalpha. J. Bone Miner. Res. 25, 769–781 (2010)

    PubMed  CAS  Google Scholar 

  7. S.C. Manolagas, From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr. Rev. 31, 266–300 (2010)

    Article  PubMed  CAS  Google Scholar 

  8. S. Zanotti, E. Canalis, Notch and the skeleton. Mol. Cell. Biol. 30, 886–896 (2010)

    Article  PubMed  CAS  Google Scholar 

  9. Y. Nam, P. Sliz, L. Song, J.C. Aster, S.C. Blacklow, Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell 124, 973–983 (2006)

    Article  PubMed  CAS  Google Scholar 

  10. V. Deregowski, E. Gazzerro, L. Priest, S. Rydziel, E. Canalis, Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/beta-Catenin but not bone morphogenetic protein signaling. J. Biol. Chem. 281, 6203–6210 (2006)

    Article  PubMed  CAS  Google Scholar 

  11. S. Zanotti, A. Smerdel-Ramoya, L. Stadmeyer, D. Durant, F. Radtke, E. Canalis, Notch inhibits osteoblast differentiation and causes osteopenia. Endocrinology 149, 3890–3899 (2008)

    Article  PubMed  CAS  Google Scholar 

  12. M.J. Hilton, X. Tu, X. Wu, S. Bai, H. Zhao, T. Kobayashi, H.M. Kronenberg, S.L. Teitelbaum, F.P. Ross, R. Kopan, F. Long, Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat. Med. 14, 306–314 (2008)

    Article  PubMed  CAS  Google Scholar 

  13. N. Sethi, X. Dai, C.G. Winter, J. Kang, Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 19, 192–205 (2011)

    Article  PubMed  CAS  Google Scholar 

  14. J. Tao, A. Erez, B. Lee, One NOTCH further: Jagged 1 in bone metastasis. Cancer Cell 19, 159–161 (2011)

    Article  PubMed  CAS  Google Scholar 

  15. S. Zanotti, A. Smerdel-Ramoya, E. Canalis, Reciprocal regulation of Notch and nuclear factor of activated T-cells (NFAT) c1 transactivation in osteoblasts. J. Biol. Chem. 286, 4576–4588 (2011)

    Article  PubMed  CAS  Google Scholar 

  16. B. Isidor, P. Lindenbaum, O. Pichon, S. Bézieau, C. Dina, S. Jacquemont, D. Martin-Coignard, C. Thauvin-Robinet, M. Le Merrer, J.L. Mandel, A. David, L. Faivre, V. Cormier-Daire, R. Redon, C. Le Caignec, Truncating mutations in the last exon of NOTCH2 cause a rare skeletal disorder with osteoporosis. Nat. Genet. 43, 306–308 (2011)

    Article  PubMed  CAS  Google Scholar 

  17. M.A. Simpson, M.D. Irving, E. Asilmaz, M.J. Gray, D. Dafou, F.V. Elmslie, S. Mansour, S.E. Holder, C.E. Brain, B.K. Burton, K.H. Kim, R.M. Pauli, S. Aftimos, H. Stewart, C.A. Kim, M. Holder-Espinasse, S.P. Robertson, W.M. Drake, R.C. Trembath, Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone loss. Nat. Genet. 43, 303–305 (2011)

    Article  PubMed  CAS  Google Scholar 

  18. M.M. Dvorak, A. Siddiqua, D.T. Ward, D.H. Carter, S.L. Dallas, E.F. Nemeth, D. Riccardi, Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calciotropic hormones. Proc. Natl Acad. Sci. USA 101, 5140–5145 (2004)

    Article  PubMed  CAS  Google Scholar 

  19. N. Chattopadhyay, S. Yano, J. Tfelt-Hansen, P. Rooney, D. Kanuparthi, S. Bandyopadhyay, X. Ren, E. Terwilliger, E.M. Brown, Mitogenic action of calcium-sensing receptor on rat calvarial osteoblasts. Endocrinology 145, 3451–3462 (2004)

    Article  PubMed  CAS  Google Scholar 

  20. T. Kameda, H. Mano, Y. Yamada, H. Takai, N. Amizuka, M. Kobori, N. Izumi, H. Kawashima, H. Ozawa, K. Ikeda, A. Kameda, Y. Hakeda, M. Kumegawa, Calcium-sensing receptor in mature osteoclasts, which are bone resorbing cells. Biochem. Biophys. Res. Commun. 245, 419–422 (1998)

    Article  PubMed  CAS  Google Scholar 

  21. E.M. Brown, R.J. MacLeod, Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. 81, 239–297 (2001)

    PubMed  CAS  Google Scholar 

  22. K. Ballen, Targeting the stem cell niche: squeezing blood from bones. Bone Marrow Transplant. 39, 655–660 (2007)

    Article  PubMed  CAS  Google Scholar 

  23. E. Canalis, Novel treatments for osteoporosis. J. Clin. Invest. 106, 177–179 (2000)

    Article  PubMed  CAS  Google Scholar 

  24. P.J. Marie, The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone 46, 571–576 (2010)

    Article  PubMed  CAS  Google Scholar 

  25. E. Canalis, A. Giustina, J.P. Bilezikian, Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357, 905–916 (2007)

    Article  PubMed  CAS  Google Scholar 

  26. R. Pacifici, T cells: critical bone regulators in health and disease. Bone 47, 461–471 (2010)

    Article  PubMed  CAS  Google Scholar 

  27. Y. Gao, X. Wu, M. Terauchi, F. Grassi, S. Galley, X. Yang, M.N. Weitzmann, R. Pacifici, T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab. 8, 132–145 (2008)

    Article  PubMed  CAS  Google Scholar 

  28. H. Tawfeek, B. Bedi, J.Y. Li, J. Adams, T. Kobayashi, M.N. Weitzmann, H.M. Kronenberg, R. Pacifici, Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS ONE 5, e12290 (2010)

    Article  PubMed  CAS  Google Scholar 

  29. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, A.B. Hodsman, E.F. Eriksen, S. Ish-Shalom, H.K. Genant, O. Wang, B.H. Mitlak, Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434–1441 (2001)

    Article  PubMed  CAS  Google Scholar 

  30. S.L. Greenspan, H.G. Bone, M.P. Ettinger, D.A. Hanley, R. Lindsay, J.R. Zanchetta, C.M. Blosch, A.L. Mathisen, S.A. Morris, T.B. Marriott, Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med. 146, 326–339 (2007)

    PubMed  Google Scholar 

  31. J.P. Bilezikian, Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr. Osteoporos. Rep. 6, 24–30 (2008)

    Article  PubMed  Google Scholar 

  32. K.G. Saag, E. Shane, S. Boonen, F. Marín, D.W. Donley, K.A. Taylor, G.P. Dalsky, R. Marcus, Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 357, 2028–2039 (2007)

    Article  PubMed  CAS  Google Scholar 

  33. K.G. Saag, J.R. Zanchetta, J.P. Devogelaer, R.A. Adler, R. Eastell, K. See, J.H. Krege, K. Krohn, M.R. Warner, Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 60, 3346–3355 (2009)

    Article  PubMed  CAS  Google Scholar 

  34. F. Cosman, R.A. Wermers, C. Recknor, K.F. Mauck, L. Xie, E.V. Glass, J.H. Krege, Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronte or raloxifene: differences between stopping and continuing the antiresorptive agent. J. Clin. Endocrinol. Metab. 94, 3772–3780 (2009)

    Article  PubMed  CAS  Google Scholar 

  35. J.S. Finkelstein, J.J. Wyland, B.Z. Leder, S.M. Burnett-Bowie, H. Lee, H. Jüppner, R.M. Neer, Effects of teriparatide retreatment in osteoporotic men and women. J. Clin. Endocrinol. Metab. 94, 2495–2501 (2009)

    Article  PubMed  CAS  Google Scholar 

  36. N.E. Cusano, J.P. Bilezikian, Teriparatide: variations on the theme of a 2-year therapeutic course. BoneKey 7, 84–87 (2010)

    Article  Google Scholar 

  37. N.E. Cusano, J.P. Bilezikian, Combination antiresorptive and osteoanabolic therapy for osteoporosis: we are not there yet. Curr. Med. Res. Opin. (2011) [Epub ahead of print, PMID 21740288]

  38. J. Compston, The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine (2011) [Epub ahead of print]

  39. S. Boonen, K. Milison, E. Gielen, D. Vanderschueren, Sequential therapy in the treatment of osteoporosis. Curr. Med. Res. Opin. 27, 1149–1155 (2011)

    Article  PubMed  CAS  Google Scholar 

  40. D.M. Black, S.L. Greenspan, K.E. Ensrud, L. Palermo, J.A. McGowan, T.F. Lang, P. Garnero, M.L. Bouxsein, J.P. Bilezikian, C.J. Rosen, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349, 1207–1215 (2003)

    Article  PubMed  CAS  Google Scholar 

  41. F. Cosman, E.F. Eriksen, C. Recknor, P.D. Miller, N. Guañabens, C. Kasperk, P. Papanastasiou, A. Readie, H. Rao, J.A. Gasser, C. Bucci-Rechtweg, S. Boonen, Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis. J. Bone Miner. Res. 26, 503–511 (2011)

    Article  PubMed  CAS  Google Scholar 

  42. J.P. Bilezikian, A. Khan, J.T. Potts Jr., M.L. Brandi, B.L. Clarke, D. Shoback, H. Jüppner, P. D’Amour, J. Fox, L. Rejnmark, L. Mosekilde, M.R. Rubin, D. Dempster, R. Gafni, M.T. Collins, J. Sliney, J. Sanders, Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target organ involvement, treatment, and challenges for future research. J. Bone Miner. Res. (2011). doi: 10.1002/jbmr.483. [Epub ahead of print]

  43. K.K. Winer, N. Sinaii, J. Reynolds, D. Peterson, K. Dowdy, G.B. Cutler Jr, Long term therapy of 12 children with chronic hypoparathyroidism: a randomized trail comparing synthetic human parathyroid hormone (1–34) vs calcitriol and calcium. J. Clin. Endocrinol. Metab. 95, 2680–2688 (2010)

    Article  PubMed  CAS  Google Scholar 

  44. M.R. Rubin, J.P. Bilezikian, Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement. Braz. Arch. Endocrinol. Metab. 54, 220–226 (2010)

    Article  Google Scholar 

  45. T. Sikjaer, L. Rejnmark, L. Rolighed, L. Heickendorff, L. Mosekilde, The effect of adding PTH(1–84) to conventional treatment of hypoparathyroidism–A randomized, placebo-controlled study. J. Bone Miner. Res. 26, 2358–2370 (2011)

    Article  PubMed  CAS  Google Scholar 

  46. W.J. Boyle, W.S. Simonet, D.L. Lacey, Osteoclast differentiation and activation. Nature 423, 337–342 (2003)

    Article  PubMed  CAS  Google Scholar 

  47. W.S. Simonet, D.L. Lacey, C.R. Dunstan, M. Kelley, M.S. Chang, R. Lüthy, H.Q. Nguyen, S. Wooden, L. Bennett, T. Boone, G. Shimamoto, M. DeRose, R. Elliott, A. Colombero, H.L. Tan, G. Trail, J. Sullivan, E. Davy, N. Bucay, L. Renshaw-Gegg, T.M. Hughes, D. Hill, W. Pattison, P. Campbell, S. Sander, G. Van, J. Tarpley, P. Derby, R. Lee, W.J. Boyle, Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309–319 (1997)

    Article  PubMed  CAS  Google Scholar 

  48. N. Bucay, I. Sarosi, C.R. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H.L. Tan, W. Xu, D.L. Lacey, W.J. Boyle, W.S. Simonet, Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260–1268 (1998)

    Article  PubMed  CAS  Google Scholar 

  49. L.C. Hofbauer, C.A. Kühne, V. Viereck, The OPG/RANKL/RANK system in metabolic bone diseases. J. Musculoskelet. Neuronal Interact. 4, 268–275 (2004)

    PubMed  CAS  Google Scholar 

  50. P.J. Kostenuik, C. Capparelli, S. Morony, S. Adamu, G. Shimamoto, V. Shen, D.L. Lacey, C.R. Dunstan, OPG and PTH-(1–34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142, 4295–4304 (2001)

    Article  PubMed  CAS  Google Scholar 

  51. P.J. Bekker, D. Holloway, A. Nakanishi, M. Arrighi, P.T. Leese, C.R. Dunstan, The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16, 348–360 (2001)

    Article  PubMed  CAS  Google Scholar 

  52. P.J. Bekker, D.L. Holloway, A.S. Rasmussen, R. Murphy, S.W. Martin, P.T. Leese, G.B. Holmes, C.R. Dunstan, A.M. DePaoli, A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19, 1059–1066 (2004)

    Article  PubMed  CAS  Google Scholar 

  53. H.G. Bone, M.A. Bolognese, C.K. Yuen, D.L. Kendler, P.D. Miller, Y.C. Yang, L. Grazette, J. San Martin, J.C. Gallagher, Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96, 972–980 (2011)

    Article  PubMed  CAS  Google Scholar 

  54. T.D. Rachner, S. Khosla, L.C. Hofbauer, Osteoporosis: now and the future. Lancet 377, 1276–1287 (2011)

    Article  PubMed  CAS  Google Scholar 

  55. S.R. Cummings, J. San Martin, M.R. McClung, E.S. Siris, R. Eastell, I.R. Reid, P. Delmas, H.B. Zoog, M. Austin, A. Wang, S. Kutilek, S. Adami, J. Zanchetta, C. Libanati, S. Siddhanti, C. Christiansen, Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756–765 (2009)

    Article  PubMed  CAS  Google Scholar 

  56. S. Boonen, J.D. Adachi, Z. Man, S.R. Cummings, K. Lippuner, O. Törring, J.C. Gallagher, J. Farrerons, A. Wang, N. Franchimont, J. San Martin, A. Grauer, M. McClung, Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J. Clin. Endocrinol. Metab. 96, 1727–1736 (2011)

    Article  PubMed  CAS  Google Scholar 

  57. C. von Keyserlingk, R. Hopkins, A. Anastasilakis, K. Toulis, R. Goeree, J.E. Tarride, F. Xie, Clinical efficacy and safety of Denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis. Semin. Arthritis Rheum. 41, 178–186 (2011)

    Article  CAS  Google Scholar 

  58. G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123, 877–884 (2010)

    Article  PubMed  CAS  Google Scholar 

  59. M.R. Smith, B. Egerdie, N. Hernández Toriz, R. Feldman, T.L. Tammela, F. Saad, J. Heracek, M. Szwedowski, C. Ke, A. Kupic, B.Z. Leder, C. Goessl, Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745–755 (2009)

    Article  PubMed  CAS  Google Scholar 

  60. G.K. Ellis, H.G. Bone, R. Chlebowski, D. Paul, S. Spadafora, J. Smith, M. Fan, S. Jun, Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J. Clin. Oncol. 26, 4875–4882 (2008)

    Article  PubMed  CAS  Google Scholar 

  61. O. Sezer, U. Heider, I. Zavrski, C.A. Kühne, L.C. Hofbauer, RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101, 2094–2098 (2003)

    Article  PubMed  CAS  Google Scholar 

  62. U. Heider, C. Langelotz, C. Jakob, I. Zavrski, C. Fleissner, J. Eucker, K. Possinger, L.C. Hofbauer, O. Sezer, Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin. Cancer Res. 9, 1436–1440 (2003)

    PubMed  CAS  Google Scholar 

  63. S. Roux, V. Meignin, J. Quillard, G. Meduri, A. Guiochon-Mantel, J.P. Fermand, E. Milgrom, X. Mariette, RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br. J. Haematol. 117, 86–92 (2002)

    Article  PubMed  CAS  Google Scholar 

  64. N. Giuliani, S. Colla, R. Sala, M. Moroni, M. Lazzaretti, S. La Monica, S. Bonomini, M. Hojden, G. Sammarelli, S. Barillè, R. Bataille, V. Rizzoli, Human myeloma cells stimulate the receptor activator of NF-kappaB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100, 4615–4621 (2002)

    Article  PubMed  CAS  Google Scholar 

  65. G.D. Roodman, Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655–1664 (2004)

    Article  PubMed  CAS  Google Scholar 

  66. A.T. Stopeck, A. Lipton, J.J. Body, G.G. Steger, K. Tonkin, R.H. de Boer, M. Lichinitser, Y. Fujiwara, D.A. Yardley, M. Viniegra, M. Fan, Q. Jiang, R. Dansey, S. Jun, A. Braun, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132–5139 (2010)

    Article  PubMed  CAS  Google Scholar 

  67. K. Fizazi, M. Carducci, M. Smith, R. Damião, J. Brown, L. Karsh, P. Milecki, N. Shore, M. Rader, H. Wang, Q. Jiang, S. Tadros, R. Dansey, C. Goessl, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813–822 (2011)

    Article  PubMed  CAS  Google Scholar 

  68. D.H. Henry, L. Costa, F. Goldwasser, V. Hirsh, V. Hungria, J. Prausova, G.V. Scagliotti, H. Sleeboom, A. Spencer, S. Vadhan-Raj, R. von Moos, W. Willenbacher, P.J. Woll, J. Wang, Q. Jiang, S. Jun, R. Dansey, H. Yeh, Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29, 1125–1132 (2011)

    Article  PubMed  CAS  Google Scholar 

  69. A.K. Gough, J. Lilley, S. Eyre, R.L. Holder, P. Emery, Generalized bone loss in patients with rheumatoid arthritis. Lancet 344, 23–27 (1994)

    Article  PubMed  CAS  Google Scholar 

  70. K. Nemeth, M. Schoppet, N. Al-Fakhri, S. Helas, R. Jessberger, L.C. Hofbauer, C. Goettsch, The role of osteoclast-associated receptor in osteoimmunology. J. Immunol. 186, 13–18 (2011)

    Article  PubMed  CAS  Google Scholar 

  71. E. Romas, N.A. Sims, D.K. Hards, M. Lindsay, J.W. Quinn, P.F. Ryan, C.R. Dunstan, T.J. Martin, M.T. Gillespie, Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am. J. Pathol. 161, 1419–1427 (2002)

    Article  PubMed  CAS  Google Scholar 

  72. S.B. Cohen, R.K. Dore, N.E. Lane, P.A. Ory, C.G. Peterfy, J.T. Sharp, D. van der Heijde, L. Zhou, W. Tsuji, R. Newmark, Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 58, 1299–1309 (2008)

    Article  PubMed  CAS  Google Scholar 

  73. M.P. Whyte, The long and the short of bone therapy. N. Engl. J. Med. 354, 860–863 (2006)

    Article  PubMed  CAS  Google Scholar 

  74. D.H. Jones, T. Nakashima, O.H. Sanchez, I. Kozieradzki, S.V. Komarova, I. Sarosi, S. Morony, E. Rubin, R. Sarao, C.V. Hojilla, V. Komnenovic, Y.Y. Kong, M. Schreiber, S.J. Dixon, S.M. Sims, R. Khokha, T. Wada, J.M. Penninger, Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692–696 (2006)

    Article  PubMed  CAS  Google Scholar 

  75. N. Frazl-Zelman, A. Valenta, P. Roschger, A. Nader, B.D. Gelb, P. Fratzl, K. Klaushofer, Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis. J. Clin. Endocrinol. Metab. 89, 1538–1547 (2004)

    Article  CAS  Google Scholar 

  76. J.Y. Gauthier, N. Chauret, W. Cromlish, S. Desmarais, T. Duong le, J.P. Falgueyret, D.B. Kimmel, S. Lamontagne, S. Léger, T. LeRiche, C.S. Li, F. Massé, D.J. McKay, D.A. Nicoll-Griffith, R.M. Oballa, J.T. Palmer, M.D. Percival, D. Riendeau, J. Robichaud, G.A. Rodan, S.B. Rodan, C. Seto, M. Thérien, V.L. Truong, M.C. Venuti, G. Wesolowski, R.N. Young, R. Zamboni, W.C. Black, The discovery of odanacatib (MK0822), a selective inhibitor of cathepsin-K. Bioorg. Med. Chem. Lett. 18, 923–928 (2008)

    Article  PubMed  CAS  Google Scholar 

  77. S. Nagase, M. Ohyama, Y. Hashimoto, M. Small, T. Kuwayama, S. Deacon, Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study. J. Clin. Pharmacol. (2011) [Epub ahead of print]

  78. H.G. Bone, M.R. McClung, C. Roux, R.R. Recker, J.A. Eisman, N. Verbruggen, C.M. Hustad, C. DaSilva, A.C. Santora, B.A. Ince, Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J. Bone Miner. Res. 25, 937–947 (2010)

    PubMed  Google Scholar 

  79. S.E. Papapoulos, Targeting sclerostin as potential treatment of osteoporosis. Ann. Rheum. Dis. 70(Suppl 1), 19–22 (2011)

    Article  CAS  Google Scholar 

  80. X. Li, M.S. Ominsky, K.S. Warmington, S. Morony, J. Gong, J. Cao, Y. Gao, V. Shalhoub, B. Tipton, R. Haldankar, Q. Chen, A. Winters, T. Boone, Z. Geng, Q.T. Niu, H.Z. Ke, P.J. Kostenuik, W.S. Simonet, D.L. Lacey, C. Paszty, Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24, 578–588 (2009)

    Article  PubMed  CAS  Google Scholar 

  81. M.S. Ominsky, F. Vlasseros, J. Jolette, S.Y. Smith, B. Stouch, G. Doellgast, J. Gong, Y. Gao, J. Cao, K. Graham, B. Tipton, J. Cai, R. Deshpande, L. Zhou, M.D. Hale, D.J. Lightwood, A.J. Henry, A.G. Popplewell, A.R. Moore, M.K. Robinson, D.L. Lacey, W.S. Simonet, C. Paszty, Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density and bone strength. J. Bone Miner. Res. 25, 948–959 (2010)

    Article  PubMed  CAS  Google Scholar 

  82. D. Padhi, G. Jang, B. Stouch, L. Fang, E. Posvar, Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26, 19–26 (2011)

    Article  PubMed  CAS  Google Scholar 

  83. R.H. Giles, J.K. van Es, H. Clevers, Caught up in a Wnt storm: Wnt signalling in cancer. Biochem. Biophys. Acta 1653, 1–24 (2003)

    PubMed  CAS  Google Scholar 

  84. M. Kansara, M. Tsang, L. Kodjabachian, N.A. Sims, M.K. Trivett, M. Ehrich, A. Dobrovic, J. Slavin, P.F. Choong, P.J. Simmons, I.B. Dawid, D.M. Thomas, Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 119, 837–851 (2009)

    Article  PubMed  CAS  Google Scholar 

  85. A.A. Khan, G.K.B. Sandor, E. Dore, A.D. Morrison, M. Alsahli, F. Amin, E. Peters, D.A. Hanley, S.R. Chaudry, B. Lentle, D.W. Dempster, F.H. Glorieux, A.J. Neville, R.M. Talwar, C.M. Clokie, M.A. Mardini, T. Paul, S. Khosla, R.G. Josse, S. Sutherland, D.K. Lam, R.P. Carmichael, N. Blanas, D. Kendler, S. Petak, L.G. Ste-Marie, J. Brown, A.W. Evans, L. Rios, J.E. Compston, Bisphosphonate associated osteonecrosis of the jaw. J. Reumathol. 36, 478–490 (2009)

    Google Scholar 

  86. J.C. Lo, F.S. O’Ryan, N.P. Gordon, J. Yang, R.L. Hui, D. Martin, M. Hutchinson, P.V. Lathon, G. Sanchez, P. Silver, M. Chandra, C.A. McCloskey, J.A. Staffa, M. Willy, J.V. Selby, A.S. Go, Predicting risk of osteonecrosis of the jaw with oral bisphosphonate exposure (PROBE) investigators. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J. Oral Maxillofac. Surg. 68, 243–253 (2010)

    Article  PubMed  Google Scholar 

  87. S.L. Ruggiero, T.B. Dodson, L.A. Assael, R. Landesberg, R.E. Marx, B. Mehrotra, American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonates-related osteonecrosis of the jaws: 2009 update. J. Oral Maxillofac. Surg. 67(Suppl 5), 2–12 (2009)

    PubMed  Google Scholar 

  88. J.E. Compston, Bisphosphonates and atypical femoral fractures: a time for reflection. Maturitas 65, 3–4 (2010)

    Article  PubMed  CAS  Google Scholar 

  89. E.M. Lewiecki, Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs 71, 791–814 (2011)

    Article  PubMed  CAS  Google Scholar 

  90. M. Pazianas, J. Compston, C.L. Huang, Atrial fibrillation and bisphosphonate therapy. J. Bone Miner. Res. 25, 2–10 (2010)

    Article  PubMed  CAS  Google Scholar 

  91. E. Barrett-Connor, A.S. Swern, C.M. Hustad, H.G. Bone, U.A. Liberman, S. Papapoulos, H. Wang, A. de Papp, A.C. Santora, Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos. Int. (2011) [Epub ahead of print]

  92. W. Wang, X. Zhang, J. Zheng, J. Yang, High glucose stimulates adipogenic and inhibits osteogenic differentiation in MG-63 cells through cAMP/protein kinase A/extracellular signalregulated kinase pathway. Mol. Cell. Biochem. 338, 115–122 (2010)

    Article  PubMed  CAS  Google Scholar 

  93. R.A. Kayal, D. Tsatsas, M.A. Bauer, B. Allen, M.O. Al-Sebaei, S. Kakar, C.W. Leone, E.F. Morgan, L.C. Gerstenfeld, T.A. Einhorn, D.T. Graves, Diminished bone formation during diabetic fracture healing is related to the premature resorption of cartilage associated with increased osteoclast activity. J. Bone Miner. Res. 22, 560–568 (2007)

    Article  PubMed  CAS  Google Scholar 

  94. Y. Hamada, S. Kitazawa, R. Kitazawa, K. Kono, S. Goto, H. Komaba, H. Fujii, Y. Yamamoto, H. Yamamoto, M. Usami, M. Fukagawa, The effects of the receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic conditions. Endocrine 38, 369–376 (2010)

    Article  PubMed  CAS  Google Scholar 

  95. M. Alikhani, Z. Alikhani, C. Boyd, C.M. MacLellan, M. Raptis, R. Liu, N. Pischon, P.C. Trackman, L. Gerstenfeld, D.T. Graves, Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 40, 345 (2007)

    Article  PubMed  CAS  Google Scholar 

  96. A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535–559 (2008)

    Article  PubMed  CAS  Google Scholar 

  97. A. Räkel, O. Sheehy, E. Rahme, J. LeLorier, Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab. 34, 193–205 (2008)

    Article  PubMed  Google Scholar 

  98. P. Vestergaard, L. Rejnmark, L. Mosekilde, Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48, 1292–1299 (2005)

    Article  PubMed  CAS  Google Scholar 

  99. P. Vestergaard, Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos. Int. 18, 427–444 (2007)

    Article  PubMed  CAS  Google Scholar 

  100. S. Bonadonna, G. Mazziotti, M. Nuzzo, A. Bianchi, A. Fusco, L. De Marinis, A. Giustina, Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J. Bone Miner. Res. 20, 1837–1844 (2005)

    Article  PubMed  Google Scholar 

  101. G. Mazziotti, A. Angeli, J.P. Bilezikian, E. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17, 144–149 (2006)

    Article  PubMed  CAS  Google Scholar 

  102. G. Mazziotti, A. Bianchi, S. Bonadonna, M. Nuzzo, V. Cimino, A. Fusco, L. De Marinis, A. Giustina, Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 21, 520–528 (2006)

    Article  PubMed  CAS  Google Scholar 

  103. G. Mazziotti, A. Bianchi, S. Bonadonna, V. Cimino, I. Patelli, A. Fusco, A. Pontecorvi, L. De Marinis, A. Giustina, Prevalence of vertebral fractures in men with acromegaly. J. Clin. Endocrinol. Metab. 93, 4649–4655 (2008)

    Article  PubMed  CAS  Google Scholar 

  104. G. Mazziotti, M. Gola, A. Bianchi, T. Porcelli, A. Giampietro, V. Cimino, M. Doga, C. Gazzaruso, L. De Marinis, A. Giustina, Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 40, 102–108 (2011)

    Article  PubMed  CAS  Google Scholar 

  105. G. Mazziotti, T. Mancini, M. Mormando, E. De Menis, A. Bianchi, M. Doga, T. Porcelli, P.P. Vescovi, L. De Marinis, A. Giustina, High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary 14, 299–306 (2011)

    Article  PubMed  CAS  Google Scholar 

  106. G. Mazziotti, T. Porcelli, M. Mormando, E. De Menis, A. Bianchi, C. Mejia, T. Mancini, L. De Marinis, A. Giustina, Vertebral fractures in males with prolactinoma. Endocrine 39, 288–293 (2011)

    Article  PubMed  CAS  Google Scholar 

  107. M. Viégas, C. Costa, A. Lopes, L. Griz, M.A. Medeiro, F. Bandeira, Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications. J. Diabetes Complications 25, 216–221 (2011)

    Article  PubMed  Google Scholar 

  108. P. Vestergaard, Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate. Calcif. Tissue. Intern. (2011) [Epub ahead of print]

  109. M.S. Molinuevo, L. Schurman, A.D. McCarthy, A.M. Cortizo, M.J. Tolosa, M.V. Gangoiti, V. Arnol, C. Sedlinsky, Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J. Bone Miner. Res. 25, 211–221 (2010)

    Article  PubMed  CAS  Google Scholar 

  110. P. Ma, B. Gu, J. Ma, X. Wu, J. Cao, H. Liu, Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase/Akt pathway. Metabolism 59, 359–366 (2010)

    Article  PubMed  CAS  Google Scholar 

  111. V. Gopalakrishnan, R.C. Vignesh, J. Arunakaran, M.M. Aruldhas, N.E. Srinivasan, Effects of glucose and its modulation by insulin and estradiol on BMSC differentiation into osteoblastic lineages. Biochem. Cell Biol. 84, 93–101 (2006)

    Article  PubMed  CAS  Google Scholar 

  112. B. Nuche-Berenguer, S. Portal-Núñez, P. Moreno, N. González, A. Acitores, A. López-Herradón, P. Esbrit, I. Valverde, M.L. Villanueva-Peñacarrillo, Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J. Cell. Physiol. 225, 585–592 (2010)

    Article  PubMed  CAS  Google Scholar 

  113. A. Grey, Skeletal consequences of thiazolidinedione therapy. Osteoporos. Int. 19, 129–137 (2008)

    Article  PubMed  CAS  Google Scholar 

  114. Y.K. Loke, S. Singh, C.D. Furberg, Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Can. Med. Assoc. J. 180, 32–39 (2009)

    Article  Google Scholar 

  115. T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, P.P. Vescovi, A. Giustina, Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 45, 784–788 (2009)

    Article  PubMed  CAS  Google Scholar 

  116. I.J. Douglas, S.J. Evans, S. Pocock, L. Smeeth, The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med. 6, e1000154 (2009)

    Article  PubMed  CAS  Google Scholar 

  117. C.R. Dormuth, G. Carney, B. Carleton, K. Bassett, J.M. Wright, Thiazolidinediones and fractures in men and women. Arch. Intern. Med. 169, 1395–1402 (2009)

    Article  PubMed  CAS  Google Scholar 

  118. I. Kanazawa, T. Yamaguchi, M. Yamamoto, M. Yamauchi, S. Yano, T. Sugimoto, Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur. J. Endocrinol. 160, 265–273 (2009)

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We acknowledge the contributions of those who lectured in the 4th Skeletal Endocrinology meeting held in Brescia on April 15th 2011: J. Compston (UK), L. Hofbauer (Germany), L. Idolazzi (Italy), S. Manolagas (USA), C. Marcocci (Italy), R. Nuti (Italy), R. Pacifici (USA), J. Potts (USA), L. Rejnmark (Denmark), L. Sinigaglia (Italy), A.H. Van Lierop (The Netherlands), P. Vestergaard (Denmark).

Disclosures

G.M. received lecture fee from Eli Lilly. J.B. is a consultant for Merck, Eli Lilly, Novartis, Amgen, Radius Pharmaceuticals, Johnson & Johnson; received research support from NPS Pharmaceuticals. E.C. is a consultant for Eli Lilly and received lecture fees from Eli Lilly and Amgen.D.C has nothing to declare. A.G. is a consultant for Eli Lilly and received lecture fees from Eli Lilly and Amgen.

Author information

Authors and Affiliations

  1. Department of Medical and Surgical Sciences, University of Brescia, Brescia, Italy

    G. Mazziotti & A. Giustina

  2. Department of Medicine, Endocrine and Bone Unit, Azienda Ospedaliera “Carlo Poma”, via Lago Paiolo 10, 46100, Mantua, Italy

    G. Mazziotti

  3. Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA

    J. Bilezikian

  4. Department of Research, Saint Francis Hospital and Medical Center, Hartford, CT, USA

    E. Canalis

  5. University of Connecticut School of Medicine, Farmington, CT, USA

    E. Canalis

  6. Department of Biomedical Sciences and Biotechnologies, University of Brescia, Brescia, Italy

    D. Cocchi

Authors
  1. G. Mazziotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Bilezikian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Canalis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Cocchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Giustina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Mazziotti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mazziotti, G., Bilezikian, J., Canalis, E. et al. New understanding and treatments for osteoporosis. Endocrine 41, 58–69 (2012). https://doi.org/10.1007/s12020-011-9570-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-011-9570-2

Keywords

Search

Navigation